Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 79.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,417 shares of the company’s stock after acquiring an additional 17,446 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Taysha Gene Therapies were worth $79,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Creative Planning bought a new position in shares of Taysha Gene Therapies during the third quarter worth about $28,000. SG Americas Securities LLC acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $129,000. Scientech Research LLC bought a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at approximately $97,000. The Manufacturers Life Insurance Company raised its position in shares of Taysha Gene Therapies by 109.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after acquiring an additional 69,487 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in Taysha Gene Therapies during the second quarter worth $413,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Trading Down 9.6 %

Taysha Gene Therapies stock opened at $1.69 on Friday. The firm has a 50-day moving average price of $2.07 and a two-hundred day moving average price of $2.44. Taysha Gene Therapies, Inc. has a 52-week low of $1.27 and a 52-week high of $4.32. The firm has a market capitalization of $346.35 million, a price-to-earnings ratio of -8.45 and a beta of 0.40. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period in the prior year, the company posted ($0.38) EPS. Sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TSHA. Canaccord Genuity Group dropped their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Needham & Company LLC dropped their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Finally, Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $6.38.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.